REFERENCE FORMULA
Reference formula
Reference basis: 100 mL
| Ingredient | Source quantity | Scaled quantity |
|---|---|---|
| Enalapril maleate | 100 mg | — |
| Preserved water without propylene glycol AEMPS | 75 mL | — |
| Simple syrup AEMPS EX022 | q.s. ad 100 mL | — |
| Citric acid monohydrate | q.s. pH 3–4 βλ. ποσότητα / see quantity | — |
REFERENCE FORMULA SCALING
Proportional quantities of the same formula
Arithmetic aid. It does not change strength, dose, method or BUD and does not authorise compounding.
Theoretical calculation sheet
CGR-ES-009 · Enalapril maleate oral solution 1 mg/mL AEMPS
Not an approved master record or batch release. BUD is not calculated.
| Ingredient | Reference | Calculated | Lot | Actual quantity |
|---|
Prerequisite formulations
Documentation
Preparation description
Oral solution: Enalapril maleate oral solution 1 mg/mL AEMPS. Additional appearance criteria are not established by the specific text reviewed. [1]
Action and use
ACE inhibitor. [1]
Specifications
pH 3–4 [1]
Light
For the finished product the source specifies:
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
Air and oxidation
No oxidative stability study of the finished mixture or inert-atmosphere requirement is provided. Use the source container. [1]
Water and solubility
Citric Acid Hydrate: JP classifies the corresponding pure raw material as very soluble in water.
Enalapril Maleate: JP classifies the corresponding pure raw material as sparingly soluble in water.
Component of base CGR-ES-002: Methyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as slightly soluble in water.
Component of base CGR-ES-002: Propyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as very slightly soluble in water.
Component of base CGR-ES-022: Sucrose: JP classifies the corresponding pure raw material as very soluble in water. [3], [4], [7], [8], [9], [10], [11]
Enalapril Maleate: JP classifies the corresponding pure raw material as sparingly soluble in water.
Component of base CGR-ES-002: Methyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as slightly soluble in water.
Component of base CGR-ES-002: Propyl Parahydroxybenzoate: JP classifies the corresponding pure raw material as very slightly soluble in water.
Component of base CGR-ES-022: Sucrose: JP classifies the corresponding pure raw material as very soluble in water. [3], [4], [7], [8], [9], [10], [11]
Humidity
Citric acid monohydrate is efflorescent in dry air; confirm hydrate identity and certificate of analysis. [3]
Temperature
For the finished product the source specifies:
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
pH and compatibility
Specification of this preparation, not a demonstrated stability range:
pH 3–4 [1]
pH 3–4 [1]
Other interactions
No complete compatibility test with added actives or alternative excipients is provided. Substitutions require separate evidence. [1]
Ingredient-specific information
Citric Acid Hydrate: raw-material water solubility is classified as very soluble by JP.
Enalapril Maleate: raw-material water solubility is classified as sparingly soluble by JP.
Component of base CGR-ES-002: Methyl Parahydroxybenzoate: raw-material water solubility is classified as slightly soluble by JP.
Component of base CGR-ES-002: Propyl Parahydroxybenzoate: raw-material water solubility is classified as very slightly soluble by JP.
Component of base CGR-ES-022: Sucrose: raw-material water solubility is classified as very soluble by JP. [3], [4], [7], [8], [9], [10], [11]
Enalapril Maleate: raw-material water solubility is classified as sparingly soluble by JP.
Component of base CGR-ES-002: Methyl Parahydroxybenzoate: raw-material water solubility is classified as slightly soluble by JP.
Component of base CGR-ES-002: Propyl Parahydroxybenzoate: raw-material water solubility is classified as very slightly soluble by JP.
Component of base CGR-ES-022: Sucrose: raw-material water solubility is classified as very soluble by JP. [3], [4], [7], [8], [9], [10], [11]
Staff protection
Risk assessment
Reference batch: 100 mL. First ingredient: Enalapril maleate, 100 mg. Independently check chemical form, units and every scale conversion before weighing.
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. [1], [13], [15]
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. [1], [13], [15]
Compounding conditions
BUD rationale
Period reported by source: 50 days closed; 30 days after opening.
This duration is a specific formulary/source instruction. This review did not verify a complete primary study establishing chemical, physical and microbiological extension for the same finished formulation.
Selected general rule: up to 35 days for an aqueous form appropriately preserved in its final composition and pH. Use 20–25 °C, or 2–8 °C only where permitted/required by the source and compatible with the dosage form. A preservative name is insufficient if it is diluted, inactivated or partitioned into another phase.
The reference-policy ceiling in this edition is the shorter of the source period above and the general ceiling. Extension needs matching active/excipients/strength, container, temperature, a stability-indicating method and the required microbiological evidence for aqueous extension. An applicable official USP–NF compounded monograph is assessed separately in its complete text.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP clarification: aw measurement is not required for every nonsterile preparation. Category assignment may use the exact composition and relevant representative examples; an uncertain or borderline formulation is best assessed by a suitable specific measurement. This edition contains no measured aw or released batch. The final preparation generally must not outlast the remaining BUD of its compounded bases/intermediates. An exception requires specific justification that physical, chemical and microbiological quality is not adversely affected. Record the final limit, intermediate preparation dates and their actual expiry dates separately.
Closed/in-use distinction: this edition’s closed-container reference ceiling is 35 days subject to its stated prerequisites. After opening use no longer than 30 days and never beyond the previously assigned overall expiry. Opening does not restart the overall BUD. [1], [6], [12], [14], [16]
This duration is a specific formulary/source instruction. This review did not verify a complete primary study establishing chemical, physical and microbiological extension for the same finished formulation.
Selected general rule: up to 35 days for an aqueous form appropriately preserved in its final composition and pH. Use 20–25 °C, or 2–8 °C only where permitted/required by the source and compatible with the dosage form. A preservative name is insufficient if it is diluted, inactivated or partitioned into another phase.
The reference-policy ceiling in this edition is the shorter of the source period above and the general ceiling. Extension needs matching active/excipients/strength, container, temperature, a stability-indicating method and the required microbiological evidence for aqueous extension. An applicable official USP–NF compounded monograph is assessed separately in its complete text.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP clarification: aw measurement is not required for every nonsterile preparation. Category assignment may use the exact composition and relevant representative examples; an uncertain or borderline formulation is best assessed by a suitable specific measurement. This edition contains no measured aw or released batch. The final preparation generally must not outlast the remaining BUD of its compounded bases/intermediates. An exception requires specific justification that physical, chemical and microbiological quality is not adversely affected. Record the final limit, intermediate preparation dates and their actual expiry dates separately.
Closed/in-use distinction: this edition’s closed-container reference ceiling is 35 days subject to its stated prerequisites. After opening use no longer than 30 days and never beyond the previously assigned overall expiry. Opening does not restart the overall BUD. [1], [6], [12], [14], [16]
Prerequisites
Preserved water without propylene glycol AEMPS: CGR-ES-002
FN/2003/EX/022 JARABE SIMPLE (84% P/V). Modificado 2020: CGR-ES-022 [1]
FN/2003/EX/022 JARABE SIMPLE (84% P/V). Modificado 2020: CGR-ES-022 [1]
Equipment
Balance with suitable minimum weight, mortar/pestle or homogeniser, mixing vessels, spatulas, thermometer for heated processes and volumetric equipment for mL quantities.
Calibrated pH meter and suitable check buffers. [1]
Calibrated pH meter and suitable check buffers. [1]
Compounding method
Dissolve active in preserved water. Make up with syrup, mix and adjust pH with citric acid if needed. [1]
Observations
Strength refers to maleate salt. Uses EX022, not EX029. [1]
Container and packaging
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
Quality control
Storage
Amber glass screw-cap bottle, 2–8 °C; protect from light. [1]
Dispensing
Dispense the exact prescribed strength. For liquids use a suitable graduated oral syringe; record dose and frequency from the prescription. [1]
Labelling
Enalapril maleate oral solution 1 mg/mL AEMPS
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: Amber glass screw-cap bottle, 2–8 °C; protect from light.
Temperature for this batch BUD: ____ [1]
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: Amber glass screw-cap bottle, 2–8 °C; protect from light.
Temperature for this batch BUD: ____ [1]
v9_controls
The numeric value is a literature reference ceiling subject to its specific conditions. No actual batch BUD has been assigned and no aw measurements have been produced. The exact formula, prerequisites, container, storage and quality evidence require approval for the actual application. The BUD clock starts when compounding begins. Use the shortest applicable supported limit and assess in-use dating separately. USP categories are a technical framework and are not presented as Greek legislation.
Independent Greek/English adaptation and organisation of facts from the cited source. This is not an official translation or publisher endorsement.
Sources and references
- FN/2021/FMT/036 ENALAPRIL MALEATO 1 MG/ML SOLUCIÓN ORAL2021PDF pp. 1–6master formula2026-10-14
- PN/L/PG/002/00 INDUMENTARIAΔιαθέσιμο κείμενο / Retrieved textPDF pp. 1–5general staff protection2026-09-10
- MHLW — Japanese Pharmacopoeia XVIII: Citric Acid HydrateJP XVIII, 2021; English textPrinted p. 769; Description; Containers and storageraw-material monograph2026-09-12
- MHLW — Japanese Pharmacopoeia XVIII: Enalapril MaleateJP XVIII, 2021; English textPrinted p. 924; Description; Containers and storageraw-material monograph2026-09-12
- ASHP — USP <795> Key Changes2023pp. 1–3: scope, water activity and staff precautionsprofessional guidance; not the licensed USP chapter2026-09-12
- Texas State Board of Pharmacy — adopted 22 TAC §291.131, nonsterile compoundingTexas Register, 7 June 2024Beyond-use dating: aw categories, 14/35/90/180 days, limits and extensionspublic regulatory implementation of USP <795> BUD framework; not Greek law2026-09-12
- MHLW — Japanese Pharmacopoeia XVIII: Methyl ParahydroxybenzoateJP XVIII, 2021; English textPrinted p. 1343; Description; Containers and storageraw-material monograph2026-09-12
- FN/2017/EX/028 AGUA CONSERVANTE SIN PROPILENGLICOL2017PDF pp. 1–2master formula2026-09-10
- MHLW — Japanese Pharmacopoeia XVIII: Propyl ParahydroxybenzoateJP XVIII, 2021; English textPrinted p. 1601; Description; Containers and storageraw-material monograph2026-09-12
- MHLW — Japanese Pharmacopoeia XVIII: SucroseJP XVIII, 2021; English textPrinted p. 1748; Description; Containers and storageraw-material monograph2026-09-12
- FN/2003/EX/022 JARABE SIMPLE (84% P/V). Modificado 20202003 / αναθ. 2020PDF pp. 2master formula2026-09-10
- Illinois IDFPR — Nonsterile Compounding Self-Inspection ReportPublic checklist, retrieved 12 September 2026pp. 15–16, Establishing beyond-use datesPublic regulatory implementation of USP <795>; not Greek law; general limits and requirements for extension2026-09-12
- NIOSH — Managing Hazardous Drug Exposures: Information for Healthcare Settings2023; DHHS (NIOSH) 2023-130Risk assessment; printed pp. 27–33, activity/formulation control tableWorkplace exposure, hierarchy of controls and activity-specific PPE; US government public-domain document2026-09-12
- USP — Compounding Standards and Beyond-Use Dates, 2022 updateNovember 2022, published by USP; public copy hosted by Mississippi Boardpp. 1–2; nonsterile tableRisk-based default categories; not product-specific stability or Greek law2026-09-12
- PIC/S — Guide to Good Practices for the Preparation of Medicinal Products in Healthcare EstablishmentsPE 010-4, 1 March 2014Chapters 1–9; Annex 2 (nonsterile liquids, creams, ointments)Professional quality-system framework; not automatic national legal adoption or certification2026-09-12
- USP — General Chapter <795> FAQsUpdated 1 November 2023Questions 52, 54–56, 60–62; PDF pp. 11–14Primary clarification of aw classification, extension prerequisites and compounded-component BUDs; not automatic Greek legal adoption2026-10-14